Listening to lead: how rare disease communities guide innovation

https://rarerevolutionmagazine.com/listening-to-lead-how-rare-disease-communities-guide-innovation/ This article has been developed and funded by Ascendis Pharma UK Ltd. Ben Whitehouse, general manager UK, Ascendis Pharma UK Ltd, underscores the importance of listening to and understanding the true patient experience in order to provide comprehensive care, and why a focus on quality of life must be central to defining meaningful outcomes By Ben Whitehouse, general manager UK, Ascendis Pharma UK Ltd. Across the UK, an estimated 3.5 million people live with a rare disease—conditions that may be uncommon individually but collectively shape millions of lives.1 Delayed diagnoses, fragmented expertise and limited treatment options mean many patients may experience challenges in accessing timely and effective care. They deserve greater visibility and understanding so that their needs are truly recognised and met.